US-based digital health startup Bodyport has completed an $11.2m series A round led by pharmaceutical firm Boehringer Ingelheim through strategic investment vehicle Boehringer Ingelheim Venture Fund (BIVF).
The round also featured investment firm and design studio Playground Global and venture capital firm Initialized Capital in addition to undisclosed other participants.
Bodyport is working on a biomarker platform designed to detect heart disease using cardiac signals from the user’s feet. It disclosed the funding alongside a research collaboration agreement with Brigham and Women’s Hospital.
The company said it has now raised $15.8m in total, and its earlier investors include Playground Global and Initialized Capital as well as accelerator operator Y Combinator.
Debbie Lin, executive director at BIVF, said: “We are very excited to work with the Bodyport team and to support an innovative technology that can develop new biomarkers in the cardiovascular space.
“Learning how the Bodyport technology could potentially complement pharmaceutical therapies for patients with various cardiovascular diseases is a tremendous opportunity.”